OCPNF (Olympus) Tax Provision : $-78 Mil (TTM As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Olympus Tax Provision?

Olympus's tax provision for the three months ended in Dec. 2024 was $-61 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was $-78 Mil.

Olympus Tax Provision Historical Data

The historical data trend for Olympus's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Olympus Tax Provision Chart

Olympus Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Tax Provision

Get a 7-Day Free Trial

-241.81

-102.49

-262.06

-331.46

-59.28

Olympus Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Tax Provision	Get a 7-Day Free Trial															-104.16	111.12	-73.56	-55.47	-60.57

Olympus Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-78 Mil.

Olympus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Olympus Corp (OTCPK:OCPNF) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

OLYMY:USA 7733:Japan OLY1:Germany

Address

Shinjuku Monolith, 2-3-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, JPN, 163-0914

Website

http://www.olympus.co.jp

Olympus is a medical device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2024, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.